Imaging of Vascular Injury With 99mTc‐Labeled Monoclonal Antiplatelet Antibody S12: Preliminary Experience in Human Percutaneous Transluminal Angioplasty

Background To evaluate the in vivo safety, biodistribution, and diagnostic accuracy of a monoclonal Fab' antibody (S12) that is specific for the platelet membrane glycoprotein (GMP-140) expressed during platelet activation at vascular injury sites, 11 peripheral percutaneous transluminal angioplasty (PTA) patients (age, 61±8 years) with severe vascular disease had serial 99mTc S12 radionuclide imaging at 5 and 90 minutes, 4–6 hours, and 20–24 hours after a total of 23 angiographically successful PTA procedures. No acute allergic reactions or hematologic toxicity occurred. Methods and Results The average PTA percent angiographic diameter stenosis (DS) at all 23 sites decreased from 85±12% to 12±11%, with a mean before-to-after-PTA change of 73±14% (p<0.01). The mean radionuclide image-derived ratio of 99mTc S12 activity in PTA versus contralateral non-PTA arterial segments for all angioplasty sites was 1.6±0.5. Vascular 99mTc S12 antibody activity was qualitatively evident in the majority (78%) of PTA sites at 4–6 hours after injection. 99mTc S12 target-to-background (muscle) ratio equaled 23±0.6 at PTA sites. Nine PTA sites (391%) had residual 99mTc S12 activity at 24 hours after injection (mean PTA site-to-contralateral artery ratio, 1.5±0.4). The mean vascular 99mTIc S12 activity ratios in 10 procedurally complicated (defined as extensive dilation [>2 cm] or grade I or greater arterial dissection) and 13 uncomplicated PIA segments were 1.9±0.5 versus 1.2±0.1, respectively (p < 0.01). The associated before-to-after-PTA angiographic improvement was significantly less in procedurally complicated PTA sites (66±12% versus 80±12% DS; p < 0.01). Conclusions 99mTc S12 activity is significantly increased at angiographically patent PIA sites that are procedurally complicated and are associated with less significant before-to-after-PIA angiographic improvement. 99mETc S12 monoclonal Fab' antibody imaging permits noninvasive identification of local vascular platelet activation resulting from angioplasty balloon injury in humans.

[1]  Platelet-Derived Growth Factor , 2020, Definitions.

[2]  V. Fuster,et al.  Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. , 1990, Journal of the American College of Cardiology.

[3]  D. S. Neblock,et al.  In vivo imaging of acute arterial thrombi with technetium-99m anti-platelet monoclonal antibody , 1990 .

[4]  P. Mosse,et al.  Balloon Catheter Injury to Rabbit Carotid Artery: I. Changes in Smooth Muscle Phenotype , 1989, Arteriosclerosis.

[5]  B. Furie,et al.  Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Hillis,et al.  Restenosis after successful coronary angioplasty. Pathophysiology and prevention. , 1988, The New England journal of medicine.

[7]  V. Fuster,et al.  Restenosis after arterial angioplasty: a hemorrheologic response to injury. , 1987, The American journal of cardiology.

[8]  R. Califf,et al.  Medical approaches to prevention of restenosis after coronary angioplasty. , 1987, Journal of the American College of Cardiology.

[9]  V. Fuster,et al.  Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. , 1986, Journal of the American College of Cardiology.

[10]  B. Furie,et al.  A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. , 1986, The Journal of clinical investigation.

[11]  V. Fuster,et al.  Influence of Arterial Damage and Wall Shear Rate on Platelet Deposition: Ex Vivo Study in a Swine Model , 1986, Arteriosclerosis.

[12]  M. Shuman,et al.  A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation , 1985, The Journal of cell biology.

[13]  N. Ratliff,et al.  Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. , 1985, Journal of the American College of Cardiology.

[14]  H. Atkins,et al.  Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibody. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. McEver,et al.  A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. , 1984, The Journal of biological chemistry.

[16]  B. Furie,et al.  A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. , 1984, The Journal of biological chemistry.

[17]  M. Welch,et al.  Noninvasive detection of coronary thrombi with In-111 platelets: concise communication. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  R. Ross,et al.  A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Strauss,et al.  An instant kit method for labeling antimyosin Fab' with technetium-99m: evaluation in an experimental myocardial infarct model. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Dake,et al.  Noncoronary angioplasty. , 1989, Radiology.

[21]  M. Brand.  Incidence ofrestenosis after successful coronary angioplasty: a time-related phenomenon , 1988 .

[22]  M. Reidy.  A reassessment of endothelial injury and arterial lesion formation. , 1985, Laboratory investigation; a journal of technical methods and pathology.